KMDANasdaqPharmaceutical PreparationsFiscal year ends December 31
KAMADA LTD
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 11, 2026
$7.61−0.15 (-1.93%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- 21.7
- Dividend yield
- –
KAMADA LTD revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q1 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Proprietary Products [Member] | $161.68M | $152.42M | $156.21M | $149.39M | $147.00M | $147.71M | $141.45M | – | – | – | – | – | 84.3% | +10.0% |
| Proprietary Products [Member] | $161.68M | $152.42M | $156.21M | $149.39M | $147.00M | – | $141.45M | – | – | – | – | – | 84.3% | +10.0% |
| Distribution | $30.17M | $29.27M | $24.25M | $25.40M | $22.52M | $19.53M | $19.51M | – | – | – | – | – | 15.7% | +34.0% |
| Distribution [Member] | $30.17M | $29.27M | $24.25M | $25.40M | $22.52M | – | $19.51M | – | – | – | – | – | 15.7% | +34.0% |
By region
From the segment and revenue-disaggregation notes of Kamada's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.